From 2022 to 2024, #GLP1 use among adults with obesity, overweight, or diabetes increased sharply, while metabolic #BariatricSurgery utilization declined by over 30%. Treatment for obesity remains limited in this population. ja.ma/4dMYnSo

0 likes 0 replies